New hope for Sjögren's: major trial tests drug to tame overactive immune system
NCT ID NCT07404865
Summary
This study is testing an investigational drug called telitacicept to see if it can reduce disease activity and improve symptoms in adults with active primary Sjögren's disease. About 250 participants will receive either the drug or a placebo for 48 weeks to compare effects. The drug works by targeting specific immune system signals to calm down the overactive B-cells thought to drive the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY SJOGREN'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Accurate Clinical Research, Inc.
RECRUITINGLake Charles, Louisiana, 70605, United States
-
Accurate Clinical Research, Inc.
RECRUITINGHouston, Texas, 77089, United States
-
Chicago Clinical Research Institute Inc
RECRUITINGChicago, Illinois, 60607, United States
Conditions
Explore the condition pages connected to this study.